iCo Therapeutics Inc (MSCL)

1.5600
+0.0800(+5.41%)
  • Volume:
    104,270
  • Bid/Ask:
    1.5500/1.5600
  • Day's Range:
    1.4100 - 1.5900
  • Type:Equity
  • Market:Canada
  • ISIN:CA80401L3083
  • CUSIP:45107J105

MSCL Overview

Prev. Close
1.48
Day's Range
1.41-1.59
Revenue
70K
Open
1.5
52 wk Range
0.8-3.2
EPS
-2.87
Volume
104,270
Market Cap
51.64M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
69,376
P/E Ratio
-
Beta
2.46
1-Year Change
73.33%
Shares Outstanding
33,099,541
Next Earnings Date
Nov. 24, 2021
What is your sentiment on iCo Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

iCo Therapeutics Inc News

iCo Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyNeutralStrong Buy
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Buy

iCo Therapeutics Inc Company Profile

iCo Therapeutics Inc Company Profile

Sector
Services
Employees
5
Market
Canada

iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.